Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma.
Morris TCM, Drake MB, Kettle PJ, McGuigan T, Leahy M, O'Dwyer M, Enright H, O'Shea T, Popat R, Oakervee HE, Yong K, Cavenagh JD, Cairns DA, Alvarez-Iglesias A, Cook G. Morris TCM, et al. Clin Hematol Int. 2021 Feb 8;3(1):27-33. doi: 10.2991/chi.k.210201.001. eCollection 2021 Mar. Clin Hematol Int. 2021. PMID: 34595464 Free PMC article.
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
Popat R, Counsell N, de Tute R, De-Silva D, Phillips EH, Cavenagh JD, Adedayo T, Braganca N, Roddie C, Streetly M, Schey S, Koh MBC, Crowe J, Morris TC, Cook G, Smith P, Clifton-Hadley L, Rabin N, Owen R, Yong K; PADIMAC investigators. Popat R, et al. Br J Haematol. 2021 May;193(3):e19-e22. doi: 10.1111/bjh.17391. Epub 2021 Mar 14. Br J Haematol. 2021. PMID: 33715154 Clinical Trial. No abstract available.
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Chan WY, Counsell N, de Tute R, De-Silva D, Phillips EH, Cavenagh J, Adedayo T, Braganca N, Roddie C, Streetly M, Schey S, Koh MBC, Crowe J, Morris TC, Cook G, Clifton-Hadley L, Rabin N, Owen RG, Popat R, Yong KL; PADIMAC investigators. Chan WY, et al. Br J Haematol. 2022 Feb;196(4):e33-e37. doi: 10.1111/bjh.17903. Epub 2021 Oct 11. Br J Haematol. 2022. PMID: 34636043 Clinical Trial. No abstract available.
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial.
de Tute RM, Cook G, Cairns DA, Brown JM, Cavenagh J, Ashcroft AJ, Snowden JA, Yong K, Tholouli E, Jenner M, Hockaday A, Drayson MT, Morris TCM, Rawstron AC, Owen RG. de Tute RM, et al. Among authors: morris tcm. Bone Marrow Transplant. 2024 Mar;59(3):431-434. doi: 10.1038/s41409-023-02164-4. Epub 2024 Jan 9. Bone Marrow Transplant. 2024. PMID: 38195983 Free article. No abstract available.
Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study.
Snowden JA, Ahmedzai SH, Cox A, Cairns DA, Ashcroft AJ, Williams C, Cavenagh JD, Hockaday A, Brown JM, Brock IW, Morris TCM, Cook G; National Cancer Research Institute Haemato-oncology Clinical Studies Group. Snowden JA, et al. Among authors: morris tcm. Bone Marrow Transplant. 2022 Oct;57(10):1507-1513. doi: 10.1038/s41409-022-01738-y. Epub 2022 Jun 29. Bone Marrow Transplant. 2022. PMID: 35768571 Free PMC article. Clinical Trial.
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma.
Ahmedzai SH, Snowden JA, Ashcroft AJ, Cairns DA, Williams C, Hockaday A, Cavenagh JD, Ademokun D, Tholouli E, Allotey D, Dhanapal V, Jenner M, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Parrish C, Brown JM, Morris TCM, Cook G; National Cancer Research Institute Haemato-Oncology Clinical Studies Group. Ahmedzai SH, et al. Among authors: morris tcm. J Clin Oncol. 2019 Jul 1;37(19):1617-1628. doi: 10.1200/JCO.18.01006. Epub 2019 Apr 10. J Clin Oncol. 2019. PMID: 30969846 Free PMC article. Clinical Trial.
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G, Royle KL, O'Connor S, Cairns DA, Ashcroft AJ, Williams CD, Hockaday A, Cavenagh JD, Snowden JA, Ademokun D, Tholouli E, Andrews VE, Jenner M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Drayson MT, Brown JM, Morris TCM; National Cancer Research Institute Haemato-oncology Clinical Studies Group. Cook G, et al. Among authors: morris tcm. Br J Haematol. 2019 May;185(3):450-467. doi: 10.1111/bjh.15782. Epub 2019 Feb 6. Br J Haematol. 2019. PMID: 30729512 Free PMC article.
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. Cook G, et al. Lancet Haematol. 2016 Jul;3(7):e340-51. doi: 10.1016/S2352-3026(16)30049-7. Lancet Haematol. 2016. PMID: 27374467 Free article. Clinical Trial.
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. Cook G, et al. Lancet Oncol. 2014 Jul;15(8):874-85. doi: 10.1016/S1470-2045(14)70245-1. Epub 2014 Jun 16. Lancet Oncol. 2014. PMID: 24948586 Clinical Trial.
53 results